$KRON
Kronos Bio, Inc. Stock $kron

$kron Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000174183023000011 Filed on March 15, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$1.200M	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.82M	$11.28M	$46.47M
YoY Change	-14.74%	-8.68%	11.16%
% of Gross Profit
Research & Development	$19.66M	$22.40M	$93.72M
YoY Change	-19.56%	-55.25%	-17.0%
% of Gross Profit
Depreciation & Amortization	$600.0K	$574.0K	$2.300M
YoY Change	0.0%	5.13%	15.0%
% of Gross Profit
Operating Expenses	$29.71M	$33.68M	$137.1M
YoY Change	-18.29%	-46.03%	-9.43%
Operating Profit	-$28.49M		-$137.1M
YoY Change	-21.65%		-9.43%
Interest Expense	$2.255M	$1.900M	$3.911M
YoY Change	2110.78%	2538.89%
% of Operating Profit
Other Income/Expense, Net	$2.255M		$3.911M
YoY Change	2110.78%		1122.19%
Pretax Income	-$26.24M	-$31.78M	-$133.2M
YoY Change	-27.65%	-49.01%	-11.83%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$26.24M	-$31.78M	-$133.2M
YoY Change	-27.65%	-49.01%	-11.83%
Net Earnings / Revenue	-2186.5%
Basic Earnings Per Share	-$0.46		-$2.37
Diluted Earnings Per Share	-$0.46	-$0.56	-$2.37
COMMON SHARES
Basic Shares Outstanding	57.63M shares	56.90M shares	56.20M shares
Diluted Shares Outstanding	57.15M shares		56.20M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$226.4M	$238.2M	$238.2M
YoY Change	-25.31%	-29.84%	-29.84%
Cash & Equivalents	$61.65M	$75.97M	$75.97M
Short-Term Investments	$164.8M	$162.2M	$162.2M
Other Short-Term Assets	$5.350M	$5.534M	$5.534M
YoY Change	-21.25%	-23.45%	-23.45%
Inventory
Prepaid Expenses
Receivables	$516.0K	$572.0K	$572.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$232.3M	$244.3M	$244.3M
YoY Change	-25.22%	-29.71%	-29.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.53M	$12.99M	$37.69M
YoY Change	-69.35%	-68.92%	-9.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$14.89M	$9.762M	$9.762M
YoY Change	21.55%
Other Assets	$1.169M	$1.167M	$3.193M
YoY Change	934.51%	941.96%	49.35%
Total Long-Term Assets	$56.76M	$50.65M	$50.65M
YoY Change	2.7%	15.31%	15.31%
TOTAL ASSETS
Total Short-Term Assets	$232.3M	$244.3M	$244.3M
Total Long-Term Assets	$56.76M	$50.65M	$50.65M
Total Assets	$289.0M	$294.9M	$294.9M
YoY Change	-21.0%	-24.66%	-24.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.039M	$5.047M	$5.047M
YoY Change	27.97%	405.71%	405.71%
Accrued Expenses	$6.598M	$12.96M	$15.31M
YoY Change	-20.77%	43.03%	37.04%
Deferred Revenue	$8.655M	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$25.26M	$21.49M	$21.49M
YoY Change	47.93%	57.68%	57.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$87.00K	$209.0K	$28.95M
YoY Change	-89.06%	-81.0%	-11.6%
Total Long-Term Liabilities	$87.00K	$209.0K	$28.95M
YoY Change	-89.06%	-81.0%	-11.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.26M	$21.49M	$21.49M
Total Long-Term Liabilities	$87.00K	$209.0K	$28.95M
Total Liabilities	$63.42M	$50.44M	$50.44M
YoY Change	29.86%	8.75%	8.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$422.4M	-$396.2M
YoY Change	41.15%	50.66%
Common Stock	$57.00K	$57.00K
YoY Change	1.79%	1.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$225.6M	$244.5M	$244.5M
YoY Change
Total Liabilities & Shareholders Equity	$289.0M	$294.9M	$294.9M
YoY Change	-21.0%	-24.66%	-24.66%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$26.24M	-$31.78M	-$133.2M
YoY Change	-27.65%	-49.01%	-11.83%
Depreciation, Depletion And Amortization	$600.0K	$574.0K	$2.300M
YoY Change	0.0%	5.13%	15.0%
Cash From Operating Activities	-$5.947M	-$22.53M	-$90.93M
YoY Change	-74.68%	-61.51%	-22.89%
INVESTING ACTIVITIES
Capital Expenditures	$126.0K	$52.00K	$577.0K
YoY Change	-65.57%	-110.88%	-86.46%
Acquisitions
YoY Change
Other Investing Activities	-$6.229M	$31.79M	-$31.65M
YoY Change	-76.01%	-18.96%	-146.55%
Cash From Investing Activities	-$6.355M	$31.74M	-$32.22M
YoY Change	-75.87%	-18.1%	-150.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$471.0K
YoY Change			-84.94%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	-716.0K	$851.0K
YoY Change	-100.0%	-168.19%	-80.92%
NET CHANGE
Cash From Operating Activities	-$5.947M	-22.53M	-$90.93M
Cash From Investing Activities	-$6.355M	31.74M	-$32.22M
Cash From Financing Activities	$0.00	-716.0K	$851.0K
Net Change In Cash	-$12.30M	8.492M	-$122.3M
YoY Change	-75.04%	-145.36%	145.87%
FREE CASH FLOW
Cash From Operating Activities	-$5.947M	-$22.53M	-$90.93M
Capital Expenditures	$126.0K	$52.00K	$577.0K
Free Cash Flow	-$6.073M	-$22.58M	-$91.50M
YoY Change	-74.54%	-61.1%	-25.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001741830
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39592
CY2022	dei	Entity Registrant Name EntityRegistrantName	Kronos Bio, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1895605
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1300 So. El Camino Real
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1300 So. El Camino Real
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	San Mateo
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	San Mateo
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94402
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94402
CY2022	dei	City Area Code CityAreaCode	650
CY2022	dei	City Area Code CityAreaCode	650
CY2022	dei	Local Phone Number LocalPhoneNumber	781-5200
CY2022	dei	Local Phone Number LocalPhoneNumber	781-5200
CY2022	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	KRON
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	204600000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57630109	shares
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	San Mateo, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75973000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198270000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	162212000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	141239000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6106000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8045000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	244291000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	347554000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	9762000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	0	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12985000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14880000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24707000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26904000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2026000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2026000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1167000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	112000	usd
CY2022Q4	us-gaap	Assets Assets	294938000	usd
CY2021Q4	us-gaap	Assets Assets	391476000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5047000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	998000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12963000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9063000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2347000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2109000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1129000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1456000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21486000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13626000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28744000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	31653000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	209000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1100000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	50439000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	46379000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56967436	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56967436	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55703327	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55703327	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	57000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	56000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	641422000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	608064000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-396188000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-262984000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-792000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-39000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	244499000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	345097000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	294938000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	391476000	usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.76
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.76
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56201398	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56201398	shares
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2266000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1977000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1605000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	975000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1055000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-54000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4025000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3195000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4130000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4786000	usd
CY2022	kron	Increase Decrease In Right Of Use Operating Assets And Liabilities Net IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet	2671000	usd
CY2021	kron	Increase Decrease In Right Of Use Operating Assets And Liabilities Net IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet	-19000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	144000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-2309000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-90926000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-117924000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	577000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4260000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	367124000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	177734000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	334979000	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	226245000	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	500000	usd
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	19473000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32222000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	63724000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	5000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	471000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3127000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	380000	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	1338000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	851000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4460000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-122297000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-49740000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200296000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	250036000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77999000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200296000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	20000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	226000	usd
CY2022	kron	Reduction Of Right Of Use Asset Due To Modification ReductionOfRightOfUseAssetDueToModification	0	usd
CY2021	kron	Reduction Of Right Of Use Asset Due To Modification ReductionOfRightOfUseAssetDueToModification	1741000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3764000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75973000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198270000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2026000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2026000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77999000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200296000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	247900000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-396200000	usd
CY2021Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Amortized Cost CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost	331976000	usd
CY2021Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Gain Before Tax CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax	2000	usd
CY2021Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Loss Before Tax CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax	41000	usd
CY2021Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale CashAndCashEquivalentAndDebtSecuritiesAvailableForSale	331937000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	61577000	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	190698000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual of research and development expenses, the fair value of investments, income tax uncertainties, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ from the Company’s estimates.</span></div>
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2000000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2000000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and investments. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management and management believes that the financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions. As of December 31, 2022 and 2021, the Company has not experienced any credit losses in such accounts or investments.</span></div>The Company is subject to a number of risks common for biopharmaceutical companies, including, but not limited to, dependency on the clinical and commercial success of its product candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition, and untested manufacturing capabilities.
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	162212000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	141239000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	9762000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	0	usd
CY2022Q4	us-gaap	Investments And Cash InvestmentsAndCash	233551000	usd
CY2021Q4	us-gaap	Investments And Cash InvestmentsAndCash	331937000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	174786000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	143014000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	9762000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	184548000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	143014000	usd
CY2022Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Amortized Cost CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost	234344000	usd
CY2022Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Gain Before Tax CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax	7000	usd
CY2022Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Loss Before Tax CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax	800000	usd
CY2022Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale CashAndCashEquivalentAndDebtSecuritiesAvailableForSale	233551000	usd
CY2022Q4	kron	Debt Securities Available For Sale Accrued Interest DebtSecuritiesAvailableForSaleAccruedInterest	572000	usd
CY2021Q4	kron	Debt Securities Available For Sale Accrued Interest DebtSecuritiesAvailableForSaleAccruedInterest	816000	usd
CY2022Q4	kron	Prepaid Equipment Service Contracts PrepaidEquipmentServiceContracts	289000	usd
CY2021Q4	kron	Prepaid Equipment Service Contracts PrepaidEquipmentServiceContracts	360000	usd
CY2022Q4	kron	Prepaid External Research And Development And Outside Services PrepaidExternalResearchAndDevelopmentAndOutsideServices	2276000	usd
CY2021Q4	kron	Prepaid External Research And Development And Outside Services PrepaidExternalResearchAndDevelopmentAndOutsideServices	3074000	usd
CY2022Q4	kron	Prepaid Software PrepaidSoftware	905000	usd
CY2021Q4	kron	Prepaid Software PrepaidSoftware	624000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1630000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2644000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	434000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	527000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6106000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8045000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18500000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18139000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5515000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3259000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12985000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14880000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2300000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2000000	usd
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	891000	usd
CY2021Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	1364000	usd
CY2022Q4	kron	Espp Withholdings Liability Current ESPPWithholdingsLiabilityCurrent	238000	usd
CY2021Q4	kron	Espp Withholdings Liability Current ESPPWithholdingsLiabilityCurrent	92000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1129000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1456000	usd
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56967436	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56967436	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55703327	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55703327	shares
CY2020Q4	kron	Common Stock Voting Rights Number Of Votes Per Common Share CommonStockVotingRightsNumberOfVotesPerCommonShare	1	vote
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.57
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	18.52
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6590400	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.33
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2730338	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.48
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1192074	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	18.54
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	673999	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.72
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7454665	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.83
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M8D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	54000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3394398	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.94
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y4M17D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	53000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4060267	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.75
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y11M8D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2000000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	23800000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	38846000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	5181000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1212000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	157000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-597000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	35400000	usd
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	49900000	usd
CY2022	kron	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares	0	shares
CY2021	kron	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares	0	shares
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-27973000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-31726000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-5017000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-7138000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	15012000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	597000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	42664000	usd
CY2022Q4	kron	Effective Income Tax Rate Reconciliation Lease Liabilities EffectiveIncomeTaxRateReconciliationLeaseLiabilities	7948000	usd
CY2021Q4	kron	Effective Income Tax Rate Reconciliation Lease Liabilities EffectiveIncomeTaxRateReconciliationLeaseLiabilities	8750000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4755000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2777000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	1093000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	1320000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	58628000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	52052000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	15963000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1296000	usd
CY2022Q4	kron	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	18857000	usd
CY2021Q4	kron	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	17000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	107261000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	66195000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	100656000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58713000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	6605000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7482000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	6316000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	6973000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	289000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	509000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6605000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7482000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	100700000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58700000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	41900000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	43503000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	12412000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	246000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	141000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1993000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	105000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	796000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3035000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	246000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022	kron	Deferred Expense Capitalized Research And Development Costs DeferredExpenseCapitalizedResearchAndDevelopmentCosts	73800000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58713000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20797000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	41943000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	37916000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	100656000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58713000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-133204000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-151078000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56201398	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56201398	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54753599	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54753599	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.37
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.37
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.76
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.76
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	31091000	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9752410	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7378118	shares
CY2020Q3	kron	Royalty Obligation Termination Period From First Commercial Sale RoyaltyObligationTerminationPeriodFromFirstCommercialSale	P10Y
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24707000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26904000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2347000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2109000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28744000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	31653000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	31091000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	33762000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	5111000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	5323000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	5700000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	4400000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5130000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5749000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5921000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5405000	usd
CY2022Q4	kron	Lessee Operating Lease Liability To Be Paid Year Five And Thereafter LesseeOperatingLeaseLiabilityToBePaidYearFiveAndThereafter	21298000	usd

Files In Submission

Name	View Source	Status
0001741830-23-000011-index-headers.html	Edgar Link	pending
0001741830-23-000011-index.html	Edgar Link	pending
0001741830-23-000011.txt	Edgar Link	pending
0001741830-23-000011-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_1.jpg	Edgar Link	pending
kron-20221231.htm	Edgar Link	pending
kron-20221231.xsd	Edgar Link	pending
kron-20221231_g1.jpg	Edgar Link	pending
kron-20221231_g10.jpg	Edgar Link	pending
kron-20221231_g11.jpg	Edgar Link	pending
kron-20221231_g12.jpg	Edgar Link	pending
kron-20221231_g13.jpg	Edgar Link	pending
kron-20221231_g14.jpg	Edgar Link	pending
kron-20221231_g15.jpg	Edgar Link	pending
kron-20221231_g16.jpg	Edgar Link	pending
kron-20221231_g2.jpg	Edgar Link	pending
kron-20221231_g3.jpg	Edgar Link	pending
kron-20221231_g4.jpg	Edgar Link	pending
kron-20221231_g5.jpg	Edgar Link	pending
kron-20221231_g6.jpg	Edgar Link	pending
kron-20221231_g7.jpg	Edgar Link	pending
kron-20221231_g8.jpg	Edgar Link	pending
kron-20221231_g9.jpg	Edgar Link	pending
kron10kfy2022ex1016.htm	Edgar Link	pending
kron10kfy2022ex231.htm	Edgar Link	pending
kron10kfy2022ex311.htm	Edgar Link	pending
kron-20221231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
kron-20221231_lab.xml	Edgar Link	unprocessable
kron-20221231_pre.xml	Edgar Link	unprocessable
kron-20221231_htm.xml	Edgar Link	completed
kron10kfy2022ex312.htm	Edgar Link	pending
kron10kfy2022ex321.htm	Edgar Link	pending
kron10kfy2022ex44.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
kron-20221231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KRON
Kronos Bio, Inc. Stock $kron

2023 Q1 Form 10-K Financial Statement

#000174183023000011 Filed on March 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRON Kronos Bio, Inc. Stock $kron

2023 Q1 Form 10-K Financial Statement

#000174183023000011 Filed on March 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRON
Kronos Bio, Inc. Stock $kron